SAN MARINO, Calif. — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe.
Tag Archives | Epeius Biotechnologies
Scientists Rediscover Gene Target for Cancer Therapy – Rexin-G Receives High-tech Validation as Strategic Anti-cancer Agent
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies.
Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world’s first and, so far only, tumor-targeted genetic medicine to be validated in the clinic. Administered as stand-alone therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has once again accomplished what standard cancer treatments and even much-touted biologics have failed to do: that is, to bring forth the benefits of remission in otherwise intractable metastatic cancers.
Epeius Biotechnologies’ Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate the development and expedite the review of potentially important new drugs.
The World’s Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies’ Rexin-G is the world’s smallest hero. Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army of these tiny nano-particles seeking out and accumulating to high concentrations within the flagrant, otherwise intractable tumors with one goal in mind: to destroy the metastatic cancers from the inside.
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
SAN MARINO, Calif., May 18 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies today announced the results of two related studies using Rexin-G®, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial in the U.S.
Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
SAN MARINO, Calif., Feb. 12 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G. Honored as the first and so far only targeted, genetic medicine that has been validated in clinical trials worldwide (Nature Reviews, Genetics, 2007), Rexin-G is designed to seek-out and destroy metastatic cancers that are resistant to chemotherapy and which have spread throughout the body.
Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer
SAN MARINO, Calif., Jan. 19 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., January 2009). Rexin-G was well tolerated and there was no dose-limiting toxicity. At Dose Level I, three patients achieved stable disease with no tumor progression; and at Dose Level II, one patient had a 37 percent decrease in tumor size and five patients exhibited disease stabilization with no tumor progression.
Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan
SAN MARINO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world’s first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body.
Epeius Biotechnologies’ Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
SAN MARINO, Calif., Sept. 15 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a recent NEWS article published by the Journal of the National Cancer Institute (JNCI, Sept. 9, 2008). The article, authored by Vickie Brower, describes recent advances and new approaches in genetic medicine that may succeed where small molecules and proteins have failed.
ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer
SAN MARINO, Calif., May 19 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et al., ASCO meeting, 2008). Continuing on with the planned dose-escalations of Rexin-G which began in 2005 using lower doses of Rexin-G in a Phase I safety study (Molecular Therapy, 2008), the current Phase I/II study employed higher dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks.
Epeius Biotechnologies Leads with Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma RandD Summit Conference in Boston
SAN MARINO, Calif. and BOSTON, Mass. – Oct. 18 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on ‘The Advent of Pathotropic Medicine for Cancer’ at the Global Pharma R&D Summit 2007 to be held in Boston.
News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
SAN MARINO, Calif. – June 4 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced the publication of a historic landmark in medical oncology and a definitive benchmark in the emerging field of cancer gene therapy. The first clinical report of its kind, Le Morte du Tumour – published in the June issue of the International Journal of Oncology, Vol.30, pp. 1297-1307 – documents the histologic features of tumor destruction observed in chemo-resistant cancers.
Epeius Biotechnologies Reaches Out to American Cancer Patients, Gains FDA Approval for Two New Clinical Trials Using Rexin-G(TM) for Breast Cancer and Sarcoma
SAN MARINO, Calif. – June 4 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA granted Orphan Drug Status for Rexin-G.
Updated: Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G as Treatment for Diverse Metastatic Cancers
SAN MARINO, Calif. and TOKYO, Japan – Dec. 6, 2006 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G(TM) in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in October, only two months ago, the initial reports are both encouraging and noteworthy.
Epeius Biotechnologies Affirms Leadership Role in The Development of Genetic Medicine
SAN MARINO, Calif. – Oct. 11 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Dr. Frederick Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak at the upcoming Global Pharmaceutical Research & Development Summit held on Oct. 24 at 4:10 p.m. (PT) in Anaheim, Calif. Dr. Hall will present the current status of global development and the broad pharmaceutical indications for the company’s innovative targeting technology platform that has enabled Epeius to develop Rexin-G(TM).
-
Nude Pregnant Kim Kardashian ‘Fertility Statue’ Unveiling in L.A.
-
International Document Services idsDoc Mortgage Document Prep System Improves Productivity and Delivers Custom Docs to Mortgage Network
-
Leawo Releases Brand-New 50,000-User-Tested Windows 8 Blu-ray Player Software at the Lowest Price Ever
-
Bankers Asset Management Uses Quandis’ Valuation System to Efficiently Complete BPOs and Manage Agents
-
Banks Flock to Financial Education to Drive Sales
-
Jeff Fest Arts and Music Festival Announces Three-day Musical Lineup with Dot Dot Dot, Magic Box, and Michael McDermott Band
-
SecuGen India is Now Open for Business
-
Mortgage Technology Magazine Names IDS to 2013 ‘Top 50 Service Providers’ List
-
Workforce Investment Board of San Bernardino County Appoints New Leadership
-
Mortgage Technology Magazine Designates Quandis a Top 50 Service Provider for Third Year in a Row
-
Members of the Hollywood Community and Military Charity Arrive in Washington, D.C. to Receive Congressional Commendations
-
EnviroIngenuity Offers High Performance Vertical Gardens for Home Use
-
For the 5th Year in a Row Mueller Offers a Metal Building to a Deserving Texas Non-Profit Organization
-
Author and Cancer Advocate Joy Cruse to speak at III Forks Golf Classic Dinner to Benefit Childhood Cancer Research
Follow Send2Press on Social Media:
Stay up to date with Send2Press on popular social portals.